Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Peter Schmid, MD, PhD, on a Possible Practice-Changing Regimen for Patients With Early-Stage, High-Risk TNBC

Posted: Thursday, February 10, 2022

Peter Schmid, MD, PhD, of Barts Cancer Institute, talks about whether the phase III findings of KEYNOTE-522, which showed a benefit to combining pembrolizumab with chemotherapy for patients with early-stage, high-risk triple-negative breast cancer, could become a practice-changing regimen.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.